Nurix Therapeutics (NRIX) Return on Equity (2020 - 2025)
Historic Return on Equity for Nurix Therapeutics (NRIX) over the last 6 years, with Q4 2025 value amounting to 0.58%.
- Nurix Therapeutics' Return on Equity fell 1500.0% to 0.58% in Q4 2025 from the same period last year, while for Nov 2025 it was 0.58%, marking a year-over-year decrease of 1500.0%. This contributed to the annual value of 0.5% for FY2025, which is 400.0% up from last year.
- Latest data reveals that Nurix Therapeutics reported Return on Equity of 0.58% as of Q4 2025, which was down 1500.0% from 0.6% recorded in Q3 2025.
- Nurix Therapeutics' Return on Equity's 5-year high stood at 0.2% during Q1 2021, with a 5-year trough of 0.78% in Q1 2024.
- Its 5-year average for Return on Equity is 0.5%, with a median of 0.55% in 2022.
- In the last 5 years, Nurix Therapeutics' Return on Equity tumbled by -3100bps in 2022 and then skyrocketed by 3700bps in 2025.
- Nurix Therapeutics' Return on Equity (Quarter) stood at 0.33% in 2021, then tumbled by -71bps to 0.56% in 2022, then fell by -19bps to 0.66% in 2023, then soared by 35bps to 0.43% in 2024, then plummeted by -36bps to 0.58% in 2025.
- Its last three reported values are 0.58% in Q4 2025, 0.6% for Q3 2025, and 0.45% during Q2 2025.